Philip Huxley BSc DPhil

Philip has 25+ years’ experience in the pharmaceutical industry and played a key role in the identification of four clinical candidates. His work focuses on translational research: turning basic science and early stage drug discovery projects into clinical candidates with data packages supporting safety, PK and in vivo proof of concept.

In the recent past Philip has worked with a variety of virtual companies in the UK and Boston – helping them to take small molecule drug discovery programs from hit identification to candidate selection. The programs have been progressed using small teams (led or co-led by Philip) and outsourced resource using CROs located in Europe, the US and India (Hyderabad).

Therapeutic area expertise
Philip has worked in diverse therapeutic areas including oncology, T2D and metabolic disease, inflammatory and autoimmune disease and CNS disorders.

Clients for chemistry (building block design and manufacture) and medicinal chemistry services have included: Ampla Pharmaceuticals Inc., Argenta, Astrazeneca, Avidex, Boehringer Ingelheim, Cellzome, Fischer Scientific, Genentech, GSK, Lilly, Millenium, MSD, Namiki Shoji Co., Novartis, Prexa Pharmaceuticals Inc., Spear Therapeutics Ltd. and WuXi.

Philip is a keen runner and coaches cross country and middle distance athletes (aged 14-55+) at Oxford City Athletic Club


Pre-clinical drug discovery
Lead Optimization
SAR analysis
Patent review and due diligence
NewCo due diligence
NewCo formation / strategy


m: + 44 7810773781
t: + 44 1993 880 504
e: philip.huxley@gatewaypharma.com

skype: Gatewaypharma
Vcard: vcard download
LinkedIn: linkedin.com/in/philiphuxley

Gatewaypharma Ltd., Registered in England and Wales, Company No 5628063